|
1
|
Sweetnam R: Osteosarcoma. Br J Hosp Med.
28:112116–121. 1982.PubMed/NCBI
|
|
2
|
Dorfman HD and Czerniak B: Bone cancers.
Cancer. 75(Suppl): 203–210. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized
osteosarcoma in young patients treated with limb-salvage surgery
and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nybakken K and Perrimon N: Hedgehog signal
transduction: Recent findings. Curr Opin Genet Dev. 12:503–511.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrova R and Joyner AL: Roles for
Hedgehog signaling in adult organ homeostasis and repair.
Development. 141:3445–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Briscoe J and Thérond PP: The mechanisms
of Hedgehog signalling and its roles in development and disease.
Nat Rev Mol Cell Biol. 14:416–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirotsu M, Setoguchi T, Sasaki H,
Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened
as a new therapeutic target for human osteosarcoma. Mol Cancer.
9:52010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagao H, Ijiri K, Hirotsu M, Ishidou Y,
Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S and
Setoguchi T: Role of GLI2 in the growth of human osteosarcoma. J
Pathol. 224:169–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagao-Kitamoto H, Setoguchi T, Kitamoto S,
Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M,
Kitajima S, et al: Ribosomal protein S3 regulates GLI2-mediated
osteosarcoma invasion. Cancer Lett. 356B:855–861. 2015. View Article : Google Scholar
|
|
11
|
Nagao-Kitamoto H, Nagata M, Nagano S, et
al: GLI2 is a novel therapeutic target for metastasis of
osteosarcoma. Int J Cancer. 136:1276–1284. 2015. View Article : Google Scholar
|
|
12
|
Yang W, Liu X, Choy E, Mankin H, Hornicek
FJ and Duan Z: Targeting hedgehog-GLI-2 pathway in osteosarcoma. J
Orthop Res. 31:502–509. 2013. View Article : Google Scholar
|
|
13
|
Nasr R, Guillemin MC, Ferhi O, Soilihi H,
Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M,
Lallemand-Breitenbach V, Gourmel B, et al: Eradication of acute
promyelocytic leukemia-initiating cells through PML-RARA
degradation. Nat Med. 14:1333–1342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beauchamp EM, Ringer L, Bulut G, Sajwan
KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O,
Macdonald TJ, et al: Arsenic trioxide inhibits human cancer cell
growth and tumor development in mice by blocking Hedgehog/GLI
pathway. J Clin Invest. 121:148–160. 2011. View Article : Google Scholar :
|
|
15
|
Nakamura S, Nagano S, Nagao H, Ishidou Y,
Yokouchi M, Abematsu M, Yamamoto T, Komiya S and Setoguchi T:
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI
transcription via DNA damage accumulation. PLoS One. 8:e694662013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwamoto Y and Tanaka K: The activity of
the Bone and Soft Tissue Tumor Study Group of the Japan Clinical
Oncology Group. Jpn J Clin Oncol. 42:467–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keating GM: Vismodegib: In locally
advanced or metastatic basal cell carcinoma. Drugs. 72:1535–1541.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Budach W, Budach V, Stuschke M, Schmauder
B, Reipke P and Scheulen ME: Efficacy of ifosfamide, dacarbazine,
doxorubicin and cisplatin in human sarcoma xenografts. Br J Cancer.
70:29–34. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gailani MR, Ståhle-Bäckdahl M, Leffell DJ,
Glynn M, Zaphiropoulos PG, Pressman C, Undén AB, Dean M, Brash DE,
Bale AE, et al: The role of the human homologue of Drosophila
patched in sporadic basal cell carcinomas. Nat Genet. 14:78–81.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie J, Murone M, Luoh SM, Ryan A, Gu Q,
Zhang C, Bonifas JM, Lam CW, Hynes M, Goddard A, et al: Activating
smoothened mutations in sporadic basal-cell carcinoma. Nature.
391:90–92. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Slade I, Murray A, Hanks S, Kumar A,
Walker L, Hargrave D, Douglas J, Stiller C, Izatt L and Rahman N:
Heterogeneity of familial medulloblastoma and contribution of
germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam
Cancer. 10:337–342. 2011. View Article : Google Scholar
|
|
24
|
Raffel C, Jenkins RB, Frederick L, Hebrink
D, Alderete B, Fults DW and James CD: Sporadic medulloblastomas
contain PTCH mutations. Cancer Res. 57:842–845. 1997.PubMed/NCBI
|
|
25
|
Reifenberger J, Wolter M, Weber RG,
Megahed M, Ruzicka T, Lichter P and Reifenberger G: Missense
mutations in SMOH in sporadic basal cell carcinomas of the skin and
primitive neuroectodermal tumors of the central nervous system.
Cancer Res. 58:1798–1803. 1998.PubMed/NCBI
|
|
26
|
Taylor MD, Liu L, Raffel C, Hui CC,
Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, et
al: Mutations in SUFU predispose to medulloblastoma. Nat Genet.
31:306–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scales SJ and de Sauvage FJ: Mechanisms of
Hedgehog pathway activation in cancer and implications for therapy.
Trends Pharmacol Sci. 30:303–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amakye D, Jagani Z and Dorsch M:
Unraveling the therapeutic potential of the Hedgehog pathway in
cancer. Nat Med. 19:1410–1422. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Basset-Seguin N, Hauschild A, Grob JJ,
Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux
C, Thomas L, et al: Vismodegib in patients with advanced basal cell
carcinoma (STEVIE): A pre-planned interim analysis of an
international, open-label trial. Lancet Oncol. 16:729–736. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berlin J, Bendell JC, Hart LL, Firdaus I,
Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL,
et al: A randomized phase II trial of vismodegib versus placebo
with FOLFOX or FOLFIRI and bevacizumab in patients with previously
untreated metastatic colorectal cancer. Clin Cancer Res.
19:258–267. 2013. View Article : Google Scholar
|
|
31
|
Kaye SB, Fehrenbacher L, Holloway R, Amit
A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, et
al: A phase II, randomized, placebo-controlled study of vismodegib
as maintenance therapy in patients with ovarian cancer in second or
third complete remission. Clin Cancer Res. 18:6509–6518. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee Y, Kawagoe R, Sasai K, Li Y, Russell
HR, Curran T and McKinnon PJ: Loss of suppressor-of-fused function
promotes tumorigenesis. Oncogene. 26:6442–6447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim J, Lee JJ, Kim J, Gardner D and Beachy
PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary
accumulation and reducing stability of the Gli2 transcriptional
effector. Proc Natl Acad Sci USA. 107:13432–13437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute
promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
35
|
Kim J, Aftab BT, Tang JY, Kim D, Lee AH,
Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al: Itraconazole
and arsenic trioxide inhibit Hedgehog pathway activation and tumor
growth associated with acquired resistance to smoothened
antagonists. Cancer Cell. 23:23–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang JY, Mackay-Wiggan JM, Aszterbaum M,
Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J,
Bickers DR, et al: Inhibiting the hedgehog pathway in patients with
the basal-cell nevus syndrome. N Engl J Med. 366:2180–2188. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kuijjer ML, Hogendoorn PC and
Cleton-Jansen AM: Genomewide analyses on high-grade osteosarcoma:
making sense of a genomically most unstable tumor. Int J Cancer.
133:2512–2521. 2013.PubMed/NCBI
|
|
38
|
Shou Y, Robinson DM, Amakye DD, Rose KL,
Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, et al: A
five-gene hedgehog signature developed as a patient preselection
tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer
Res. 21:585–593. 2015. View Article : Google Scholar
|
